Vistagen to present at the 2024 american society of clinical psychopharmacology (ascp) conference

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters highlighting fasedienol, its investigational pherine candidate in phase 3 development for the acute treatment of social anxiety disorder (sad), and itruvone, its investigational pherine candidate in phase 2.
VTGN Ratings Summary
VTGN Quant Ranking